Multiple Myeloma Coverage from Every Angle

Paul G. Richardson, MD, on Multiple Myeloma: Results From the OPTIMISMM Trial

Posted: Wednesday, June 6, 2018

Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discusses phase III study findings on pomalidomide, bortezomib, and low-dose dexamethasone vs bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed or refractory multiple myeloma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.